4.5 Article

CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration

期刊

BMJ-BRITISH MEDICAL JOURNAL
卷 350, 期 -, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/bmj.h1793

关键词

-

资金

  1. Alberta Advanced Education and Technology
  2. Alberta Innovates - Health Solutions (AHIS)
  3. Boiron
  4. Afexa Life Sciences
  5. Hecht Foundation
  6. HEEL
  7. Pfizer USA
  8. Schwabe Pharma
  9. Canadian Institutes for Health Research [86766]
  10. AHIS
  11. MRC [MR/J004871/1] Funding Source: UKRI
  12. Cancer Research UK [16895] Funding Source: researchfish
  13. Medical Research Council [MR/J004871/1] Funding Source: researchfish

向作者/读者索取更多资源

N-of-1 trials are a useful tool for clinicians who want to determine the effectiveness of a treatment in a particular individual. The reporting of N-of-1 trials has been variable and incomplete, hindering their usefulness in clinical decision making and by future researchers. This document presents the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015). CENT 2015 extends the CONSORT 2010 guidance to facilitate the preparation and appraisal of reports of an individual N-of-1 trial or a series of prospectively planned, multiple, crossover N-of-1 trials. CENT 2015 elaborates on 14 items of the CONSORT 2010 checklist, totalling 25 checklist items (44 sub-items), and recommends diagrams to help authors document the progress of one participant through a trial or more than one participant through a trial or series of trials, as applicable. Examples of good reporting and evidence based rationale for CENT 2015 checklist items are provided.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据